Antisense Therapeutics Valuation
| ATHJF Stock | USD 0.04 0.00 0.00% |
Antisense Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Antisense Therapeutics from analyzing the firm fundamentals such as Operating Margin of (3.28) %, shares outstanding of 669.04 M, and Return On Equity of -0.43 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Antisense Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Antisense Therapeutics is based on 3 months time horizon. Increasing Antisense Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Antisense pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Antisense Therapeutics Limited. Since Antisense Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Antisense Pink Sheet. However, Antisense Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.042 | Real 0.0316 | Hype 0.04 | Naive 0.0443 |
The real value of Antisense Pink Sheet, also known as its intrinsic value, is the underlying worth of Antisense Therapeutics Company, which is reflected in its stock price. It is based on Antisense Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Antisense Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Antisense Therapeutics Limited helps investors to forecast how Antisense pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Antisense Therapeutics more accurately as focusing exclusively on Antisense Therapeutics' fundamentals will not take into account other important factors: Antisense Therapeutics Total Value Analysis
Antisense Therapeutics Limited is presently forecasted to have takeover price of 27.82 M with market capitalization of 41.78 M, debt of 227.4 K, and cash on hands of 19.23 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Antisense Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
27.82 M | 41.78 M | 227.4 K | 19.23 M |
Antisense Therapeutics Investor Information
About 19.0% of the company shares are held by company insiders. The book value of Antisense Therapeutics was presently reported as 0.03. The company recorded a loss per share of 0.01. Antisense Therapeutics had not issued any dividends in recent years. The entity had 50:49 split on the 10th of April 2018. Based on the key indicators related to Antisense Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Antisense Therapeutics Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Antisense Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Antisense Therapeutics has an asset utilization ratio of 7.92 percent. This implies that the Company is making $0.0792 for each dollar of assets. An increasing asset utilization means that Antisense Therapeutics Limited is more efficient with each dollar of assets it utilizes for everyday operations.Antisense Therapeutics Ownership Allocation
Antisense Therapeutics holds a total of 669.04 Million outstanding shares. Antisense Therapeutics Limited shows 19.3 percent of its outstanding shares held by insiders and 4.93 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Antisense Therapeutics Profitability Analysis
The company reported the revenue of 1.78 M. Net Loss for the year was (5.81 M) with profit before overhead, payroll, taxes, and interest of 1.71 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Antisense Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Antisense Therapeutics and how it compares across the competition.
About Antisense Therapeutics Valuation
The pink sheet valuation mechanism determines Antisense Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Antisense Therapeutics. We calculate exposure to Antisense Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Antisense Therapeutics's related companies.Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Antisense Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Antisense Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Antisense Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Antisense Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Antisense Therapeutics' revenue streams: Identify Antisense Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Antisense Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Antisense Therapeutics' growth potential: Evaluate Antisense Therapeutics' management, business model, and growth potential.
- Determine Antisense Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Antisense Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Antisense Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Antisense Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 668.8 M | |
| Retained Earnings | -80.9 M | |
| Shares Float | 532.6 M |
Complementary Tools for Antisense Pink Sheet analysis
When running Antisense Therapeutics' price analysis, check to measure Antisense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Antisense Therapeutics is operating at the current time. Most of Antisense Therapeutics' value examination focuses on studying past and present price action to predict the probability of Antisense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Antisense Therapeutics' price. Additionally, you may evaluate how the addition of Antisense Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |